Cory Kasimov
Stock Analyst
(4.40)
# 3,889
Out of 4,648 analysts
71
Total ratings
51.02%
Success rate
22.75%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $66.20 | +58.61% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $830.35 | +41.51% | 5 | Oct 24, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $50 → $45 | $25.34 | +77.58% | 2 | Aug 7, 2024 | |
| MRNA Moderna | Maintains: In-Line | $120 | $53.66 | +123.63% | 4 | Jun 27, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $87.64 | -3.01% | 1 | May 14, 2024 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $175 | $120.08 | +45.74% | 1 | May 14, 2024 | |
| BNTX BioNTech SE | Initiates: In-Line | $100 | $109.60 | -8.76% | 3 | May 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $84 → $88 | $51.20 | +71.88% | 6 | Feb 27, 2024 | |
| BIIB Biogen | Maintains: Neutral | $324 → $276 | $173.84 | +58.77% | 4 | Dec 21, 2021 | |
| SANA Sana Biotechnology | Initiates: Neutral | $35 | $3.78 | +827.15% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $76 → $39 | $0.46 | +8,314.24% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $316.59 | -26.72% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $75.75 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $89.80 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $26.68 | -21.29% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $2.94 | +683.65% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $11.81 | +2,017.75% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.22 | +723.05% | 1 | Feb 14, 2018 |
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $66.20
Upside: +58.61%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $830.35
Upside: +41.51%
BridgeBio Pharma
Aug 7, 2024
Maintains: Outperform
Price Target: $50 → $45
Current: $25.34
Upside: +77.58%
Moderna
Jun 27, 2024
Maintains: In-Line
Price Target: $120
Current: $53.66
Upside: +123.63%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $87.64
Upside: -3.01%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $120.08
Upside: +45.74%
BioNTech SE
May 14, 2024
Initiates: In-Line
Price Target: $100
Current: $109.60
Upside: -8.76%
Ultragenyx Pharmaceutical
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $51.20
Upside: +71.88%
Biogen
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $173.84
Upside: +58.77%
Sana Biotechnology
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.78
Upside: +827.15%
Feb 17, 2021
Downgrades: Neutral
Price Target: $76 → $39
Current: $0.46
Upside: +8,314.24%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $316.59
Upside: -26.72%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $75.75
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $89.80
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $26.68
Upside: -21.29%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $2.94
Upside: +683.65%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $11.81
Upside: +2,017.75%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.22
Upside: +723.05%